BiotechTube

CDP870

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Active Rheumatoid Arthritis

Conditions

Active Rheumatoid Arthritis

Trial Timeline

Jan 1, 2011 → May 1, 2013

NCT ID
NCT02586246

About CDP870

CDP870 is a phase 3 stage product being developed by Astellas Pharma for Active Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02586246. Target conditions include Active Rheumatoid Arthritis.

What happened to similar drugs?

20 of 20 similar drugs in Active Rheumatoid Arthritis were approved

Approved (20) Terminated (1) Active (0)
✅mirabegron + solifenacinAstellas PharmaApproved
✅Mirabegron + PlaceboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
✅Mirabegron + Tolterodine ERAstellas PharmaApproved
✅Alpha blocker + placebo + solifenacinAstellas PharmaApproved
✅Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02586246Phase 3Completed

Competing Products

20 competing products in Active Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
mirabegron + solifenacinAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaApproved
43
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
BetanisAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaApproved
43
SolifenacinAstellas PharmaPhase 2
35
Mirabegron + Tolterodine ERAstellas PharmaApproved
43
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
26
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
warfarin + YM178Astellas PharmaPhase 1
29
Solifenacin succinateAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved
43